Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610559917/en/
Contacts
Investor Contact: Andrew McKibbenir@mirumpharma.com
Media Contact: Erin Murphymedia@mirumpharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
National Vision Releases Annual Sustainability Report Highlighting 2024 Progress
DULUTH, Ga.--(BUSINESS WIRE)--National Vision, Inc., one of the largest optical retail companies in the U.S., released its 2024 Sustainability Report, 'A World Worth Seeing.' The report focuses on the company's performance across its Social, Employees, Environment and Governance (SEE+G) framework, and reflects continued progress against the environmental, social and governance (ESG) issues that matter most to the company's business and stakeholders. "This past year, our refreshed leadership team made significant strides to accelerate our business transformation, including the implementation of new strategic initiatives to expand our customer base, enhance profitability and create long-term value for shareholders,' said CEO Reade Fahs. 'Alongside these advancements, we continued our mission of increasing accessibility and sustainability, never wavering in our commitment to provide essential eye care and eyewear to communities around the country and around the world." Highlights from the 2024 Sustainability Report include: Social: Impacted more than 1.1 million lives through National Vision's philanthropic activities Impacted more than 1.1 million lives through National Vision's philanthropic activities Employees: Strengthened commitment to internal development, with more than half of new managers promoted from within National Vision Strengthened commitment to internal development, with more than half of new managers promoted from within National Vision Environment: Implemented waste reduction measures across National Vision's network of labs and stores, eliminating most of the need for paper and achieving considerable paper savings Implemented waste reduction measures across National Vision's network of labs and stores, eliminating most of the need for paper and achieving considerable paper savings Governance: Advanced 3rd party risk management, including publishing a first-ever Sustainable Supply Chain Strategy The report is aligned with recognized guidelines including those developed by the Sustainability Accounting Standards Board (SASB), the Global Reporting Initiative (GRI) Standards and the United Nations' Sustainable Development Goals. The report is available online at About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ: EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America's Best, Eyeglass World, and Vista Opticals inside select Fred Meyer stores and on select military bases, and an e-commerce website offering a variety of products and services for customers' eye care needs. For more information, please visit
Business Wire
23 minutes ago
- Business Wire
Solaris Energy Infrastructure Announces Dual Listing on NYSE Texas
HOUSTON--(BUSINESS WIRE)--Solaris Energy Infrastructure, Inc. (NYSE: SEI) ('Solaris') announced today the dual listing of its Class A common stock on NYSE Texas, Inc. ('NYSE Texas'), the newly launched fully electronic equities exchange headquartered in Dallas, Texas. Solaris will maintain its primary listing on the New York Stock Exchange ('NYSE') and continue to trade under the same ticker symbol, 'SEI,' on the NYSE and NYSE Texas. 'We are pleased to join the NYSE Texas as a Founding Member. Solaris is proud of its longstanding presence in Texas, where the company was established and continues to be headquartered. Many of our customers, suppliers and employees are also based in Texas or have a significant presence here, and we are excited to further support Texas business development with this dual listing,' said Bill Zartler, Solaris' Chairman and Chief Executive Officer. 'Solaris is a key provider of energy and power solutions in Texas, and we are honored to welcome them to NYSE Texas as a Founding Member,' said Chris Taylor, Chief Development Officer, NYSE Group. About Solaris Solaris Energy Infrastructure, Inc. (NYSE: SEI) provides mobile and scalable equipment-based solutions for use in distributed power generation as well as the management of raw materials used in the completion of oil and natural gas wells. Headquartered in Houston, Texas, Solaris serves multiple U.S. end markets, including energy, data centers, and other commercial and industrial sectors. For more details, visit
Yahoo
29 minutes ago
- Yahoo
Will Carvana Continue to Build on Its Cash Flow Strength in 2025?
Carvana's CVNA primary sources of operating cash flows are derived from the sale of retail vehicles, wholesale vehicles, originated loans and complementary products, including vehicle service contracts, GAP waiver coverage and other related offerings. The main uses of cash in operating activities include inventory purchases, personnel-related expenses and customer acquisition costs. For the years ended Dec. 31, 2024 and 2023, Carvana generated $918 million and $803 million in cash from operating activities, respectively. The $115 million year-over-year increase was largely driven by improved operating performance and a $274 million reduction in interest paid, attributed to higher paid-in-kind (PIK) interest on the Senior Secured Notes in 2024. PIK allows companies to conserve cash in the near term and is commonly utilized by rapidly growing 2024, Carvana's operating performance strengthened due to higher unit sales and record annual revenues, leading to significant profitability milestones. The used car retailer reported an all-time high net income, adjusted EBITDA and GAAP operating income. Carvana anticipates sequential growth in both retail units sold and adjusted EBITDA in the second quarter, projecting new all-time company records for both measures. Expected improvement in the company's operating performance will continue to drive its operating cash addition to operating cash flows, Carvana generates cash through financing activities, including short-term revolving inventory and finance receivable facilities, real estate and equipment financing, debt issuances and equity offerings. Historically, these financing activities have supported the company's growth, market expansion and strategic initiatives and this trend is expected to continue. Cash provided by and used in financing activities totaled $261 million in 2024 and $868 million in 2023. CVNA carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cash Flow Performance of CVNA's Competitors In 2024, Group 1 Automotive, Inc. GPI reported a $396.1 million increase in net cash provided by operating activities compared to the prior year. However, on an adjusted basis, Group 1's operating cash flow declined $36.9 million due to a $103.5 million drop in net income and a $440.1 million reduction in floorplan notes Motors, Inc. LAD reported a $897.5 million year-over-year rise in operating cash flow in 2024, driven by its maturing financing receivables portfolio and lower inventory levels at more established locations. Lithia's current free cash flow deployment strategy allocates 35-45% toward acquisitions, 25% toward capital expenditures, innovation and diversification and 30-40% toward shareholder returns through dividends and share repurchases. Carvana's Price Performance, Valuation and Estimates Carvana has outperformed the Zacks Internet – Commerce industry year to date. CVNA shares have surged 65.4% compared with the industry's growth of 11.4%. YTD Price Performance Image Source: Zacks Investment Research From a valuation perspective, Carvana appears overvalued. Going by its price/sales ratio, the company is trading at a forward sales multiple of 3.46, higher than its industry's 2.17. Image Source: Zacks Investment Research EPS Estimates Revision The Zacks Consensus Estimate for 2025 and 2026 EPS has moved up 5 cents and 8 cents, respectively, in the past seven days. Image Source: Zacks Investment Research Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Group 1 Automotive, Inc. (GPI) : Free Stock Analysis Report Lithia Motors, Inc. (LAD) : Free Stock Analysis Report Carvana Co. (CVNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
